Schedule a Call Back
Trump 2.0 may boost Indian pharma opportunities
Industry News- Nov 21,24
Experts highlight that higher tariffs on Chinese goods might enable Indian firms to fill supply gaps in the US generic drug market, a critical region that accounts for 30% of Indian pharma sales and 40% of global volume share.
The Trump administration's potential return, with its emphasis on the ‘China Plus One’ strategy and supply chain diversification, could provide significant opportunities for Indian pharmaceutical companies. Experts highlight that higher tariffs on Chinese goods might enable Indian firms to fill supply gaps in the US generic drug market, a critical region that accounts for 30% of Indian pharma sales and 40% of global volume share.
Sujay Shetty, Global Health Industries Advisory Leader, PwC India, noted that the Trump agenda, with its focus on ‘America First’, low taxes, and inflation control, presents a mix of opportunities and challenges. Initiatives like the Biosecure Act and potential pricing pressures may require Indian companies to enhance their supply chain capabilities and navigate evolving localisation rules.
Indian pharma has already seen increased contract manufacturing opportunities from global majors.
The proposed Biosecure Act could further benefit Indian Contract Development and Manufacturing Organizations (CDMOs) by fostering strategic alliances with US-based innovators. Kinjal Shah, Senior VP, ICRA, emphasised the need for investments in regulatory compliant facilities and advanced technologies to capitalise on rising demand.
However, risks remain. A potential 10% tariff on imports to the US could negatively impact Indian pharma exporters, according to Krishnanath Munde, Associate Director, India Ratings & Research. Nonetheless, the medium-term outlook appears favourable, as the China Plus One strategy and the Biosecure Act are expected to create larger growth opportunities.
While the specifics of Trump’s second-term policies are yet to be fully outlined, key themes like trade protectionism and reduced dependence on China indicate promising prospects for India’s well-established pharmaceutical sector.
(TOI)
Related Stories
Auto & Auto Components
EV transition and tariff wars redefine India’s auto components play
India’s auto component industry is poised to hit $ 145 billion by FY30 from $ 80 billion in FY25. Yet high US tariff, EV transition and heavy reliance on imports from China expose vulnerabilities,..
Read moreProcess Equipment
Tata Chemicals Arm to Acquire Novabay Premium Bicarbonate AP
Tata Chemicals’ unit TCIPL will acquire Novabay, a premium sodium bicarbonate maker in Asia-Pacific, strengthening TCL’s specialty portfolio and capacity to serve pharmaceutical and food custome..
Read moreAuto & Auto Components
Steep US tariffs put Indian auto-component exporters at risk: Sruthi Thomas
The Indian auto-component sector is expected to continue its growth trajectory over the near to medium term, given underlying tailwinds.
Read moreRelated Products
Programmable Controllers - Pcd-33a Series
CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS
Pro-Med Instruments (P) Ltd offers a wide range of programmable controllers - PCD-33A Series.
Gasket Graphite Powder
CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS
Arihant Packing & Gasket Company offers a wide range of gasket graphite powder.
Asahi Kasei expands 3D printing filament sales in North America
CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS
Asahi Kasei, a leading resin and compounding technology provider, has initiated the sales of 3D printing (3DP) filaments in North America through Asahi Kasei Plastics North America (APNA). The soft la Read more
latest News
Subscribe to iNoW
For Industry News on WhatsApp, Give a Miss Call on: +91 84228 74016
